BRCA2 and familial pancreatic carcinoma: As shown repeatedly in both ovarian and breast cancer, the commended POLO trial has strengthened the encouragement for PARP inhibition in solid tumors, now likely setting a new standard of care in pancreatic cancer for those with germline BRCA1 or BRCA2 mutations.